What is it about?
We reported that immunosuppressive drugs were the most common drugs used in Thailand and had an overall response rate of around 70%. However, approximately 40% of the response patients relapsed which activates the need for additional treatment to reduce the relapse rate and prolong remission.
Featured Image
Why is it important?
Few articles about the second-line treatment of primary warm-type AIHA in Asia have been published. Therefore, most physicians in Asia choose second-line treatment based on the existing data on Caucasian studies and on their personal experience. This article will help clinicians make decisions when they need to choose such treatment.
Perspectives
This article provided the whole picture of the second-line treatment of primary warm-type autoimmune hemolytic anemia in Thailand. We found that rituximab was prescribed for only 1 patient at the largest-tertiary-care hospital because it has high cost and it is not covered by the national health insurance schemes in Thailand, although rituximab shows high overall response rate. This finding provides an area of improvement of the second-line treatment of AIHA in Thailand.
Dr Chattree Hantaweepant
Siriraj Hospital Mahidol University
Read the Original
This page is a summary of: Efficacy and safety of second-line treatment in Thai patients with primary warm-type autoimmune hemolytic anemia, Hematology, January 2019, Taylor & Francis,
DOI: 10.1080/16078454.2019.1671060.
You can read the full text:
Contributors
The following have contributed to this page
